John Kuruvilla

25PUBLICATIONS
84CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumoursRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jul 27, 2026
First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.

|Jun 15, 2026
Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

|Feb 25, 2026
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.

Emmanuel Bachy, James Harnett, Katharina Prochazka

|Jan 30, 2026
Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Tomohiro Aoki, Gerben Duns, Shinya Rai

|Jan 05, 2026
Management of relapsed/refractory DLBCL in the era of novel agents and new approaches.

Inna Y Gong, John Kuruvilla

|Jun 23, 2025
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy.

John Kuruvilla, Dipenkumar Modi, Armando Santoro

Pageof 5

Frequent Collaborators

5 joint publications

Michael Crump

3 joint publications

Robert Kridel

3 joint publications

Diego Villa

3 joint publications

Anca Prica